Chemoradionuclide therapy with186re-labeled liposomal doxorubicin in combination with radiofrequency ablation for effective treatment of head and neck cancer in a nude rat tumor xenograft model

Radiology

Volumn 261, Issue 3, 2011, Pages 813-823

  Soundararajan, Anuradha ^a   Dodd III, Gerald D ^c   Bao, Ande ^a   Phillips, William T ^a   McManus, Linda M ^b   Prihoda, Thomas J ^b   Goins, Beth A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; DOXORUBICIN RE 186; FLUORODEOXYGLUCOSE F 18; LIPOSOME; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; RHENIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMORADIONUCLIDE THERAPY; CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ADJUVANT CHEMOTHERAPY; ANALYSIS OF VARIANCE; ANIMAL; CATHETER ABLATION; DISEASE MODEL; DRUG POTENTIATION; HEAD AND NECK TUMOR; ISOTOPE LABELING; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NUCLEAR MEDICINE; NUDE RAT; RANDOMIZATION; SCINTISCANNING; XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; ISOTOPE LABELING; LIPOSOMES; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS; RANDOM ALLOCATION; RATS; RATS, NUDE; RHENIUM; TRANSPLANTATION, HETEROLOGOUS;

EID: 81555207965     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11110361     Document Type: Article

References (43)

1. Kies MS, Bennett CL, Vokes EE. Locally advanced head and neck cancer. Curr Treat Options Oncol 2001; 2 (1): 7-13.
2. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328 (3): 184-194.
3. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006; 6 (8): 583-592. (Pubitemid 44140857)
4. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350 (19): 1945-1952. (Pubitemid 38580197)
5. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350 (19): 1937-1944.
6. Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25 (26): 4118-4126. (Pubitemid 47492956)
7. Lammers T, Subr V, Ulbrich K, et al. HPMA-based polymer therapeutics improve the efficacy of surgery, of radiotherapy and of chemotherapy combinations. Nanomedicine (Lond) 2010; 5 (10): 1501-1523.
8. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4 (2): 145-160. (Pubitemid 40282557)
9. 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 2003; 44 (12): 1992-1999.
10. 186Re- liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 2008; 14 (12): 3975-3983.
11. 186Re-liposome therapy in ovarian cancer xenograft model of peritoneal carcinomatosis. J Drug Target 2008; 16 (7): 626-637.
12. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003; 42 (5): 419-436. (Pubitemid 36649037)
13. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 2006; 16 (3): 175-183. (Pubitemid 44358991)
14. Harrington KJ, Lewanski C, Northcote AD, et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) as induction chemotherapy for patients with squamous cell cancer of the head and neck. Eur J Cancer 2001; 37 (16): 2015-2022. (Pubitemid 32938104)
15. Harrington KJ, Rowlinson-Busza G, Uster PS, Stewart JS. Pegylated liposome-encapsulated doxorubicin and cisplatin in the treatment of head and neck xenograft tumours. Cancer Chemother Pharmacol 2000; 46 (1): 10-18. (Pubitemid 30432169)
16. Harrington KJ, Rowlinson-Busza G, Syrigos KN, et al. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 2000; 6 (12): 4939-4949. (Pubitemid 32110440)
17. Dupuy DE, Goldberg SN. Image-guided radiofrequency tumor ablation: challenges and opportunities-part II. J Vasc Interv Radiol 2001; 12 (10): 1135-1148. (Pubitemid 32983350)
18. Goldberg SN, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities-part I. J Vasc Interv Radiol 2001; 12 (9): 1021-1032. (Pubitemid 32844849)
19. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant IV liposomal doxorubicin increases tissue coagulation and intratumoural drug accumulation. Int J Hyperthermia 2004; 20 (7): 781-802. (Pubitemid 39496856)
20. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005; 235 (2): 469-477. (Pubitemid 40571084)
21. Yang W, Ahmed M, Elian M, et al. Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology 2010; 257 (3): 685-696.
22. Hakimé A, Hines-Peralta A, Peddi H, et al. Combination of radiofrequency ablation with antiangiogenic therapy for tumor abto lation efficacy: study in mice. Radiology 2007; 244 (2): 464-470. (Pubitemid 47080878)
23. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 2006; 240 (1): 82-89. (Pubitemid 43902597)
24. Horkan C, Dalal K, Coderre JA, et al. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology 2005; 235 (1): 81-88. (Pubitemid 40432240)
25. Weinberg BD, Krupka TM, Haaga JR, Exner AA. Combination of sensitizing pretreatment and radiofrequency tumor ablation: evaluation in rat model. Radiology 2008; 246 (3): 796-803.
26. Head HW, Dodd GD III, Bao A, et al. Combination radiofrequency ablation and intravenous radiolabeled liposomal doxorubicin: imaging and quantification of increased drug delivery to tumors. Radiology 2010; 255 (2): 405-414.
27. Solazzo SA, Ahmed M, Schor-Bardach R, et al. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology 2010; 255 (1): 62-74.
28. Zweit J. Radionuclides and carrier molecules for therapy. Phys Med Biol 1996; 41 (10): 1905-1914. (Pubitemid 26333630)
29. Bao A, Phillips WT, Goins B, et al. Setup and characterization of a human head and neck squamous cell carcinoma xenograft model in nude rats. Otolaryngol Head Neck Surg 2006; 135 (6): 853-857. (Pubitemid 44820627)
30. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24 (3): 148-154. (Pubitemid 19163397)
31. Ahmed M, Lukyanov AN, Torchilin V, Tournier H, Schneider AN, Goldberg SN. Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005; 16 (10): 1365-1371. (Pubitemid 41463995)
32. 186Re-liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft model. Nucl Med Biol 2009; 36 (5): 515-524.
33. Vrekoussis T, Chaniotis V, Navrozoglou I, et al. Image analysis of breast cancer immunohistochemistry-stained sections using ImageJ: an RGB-based model. Anticancer Res 2009; 29 (12): 4995-4998.
34. Dodd GD III, Soulen MC, Kane RA, et al. Minimally invasive treatment of malignant hepatic tumors: at the threshold of a major breakthrough. RadioGraphics 2000; 20 (1): 9-27.
35. Lammers T, Kiessling F, Hennink WE, Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol Pharm 2010; 7 (6): 1899-1912.
36. Goldberg SN, Girnan GD, Lukyanov AN, et al. Percutaneous tumor ablation: increased necrosis with combined radiofrequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology 2002; 222 (3): 797-804. (Pubitemid 34215233)
37. 186Re-labeled liposomal doxorubicin: toxicity, dosimetry, and therapeutic response. Cancer Biother Radiopharm doi:10.1089/cbr.2010.0948. Published online August 11, 2011. Accessed August 29, 2011.
38. Aytac U, Claret FX, Ho L, et al. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 2001; 61 (19): 7204-7210. (Pubitemid 32946516)
39. Fornari FA Jr, Jarvis WD, Grant S, et al. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 1994; 5 (7): 723-733. (Pubitemid 24245303)
40. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA. Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 1994; 45 (4): 649-656. (Pubitemid 24139191)
41. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R. Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 1996; 49 (5): 832-841.
42. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999; 9 (2 Suppl 1): 12-26. (Pubitemid 29190407)
43. Supiot S, Gouard S, Charrier J, et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005; 11 (19 Pt 2): 7047s-7052s. (Pubitemid 41428703)